PRIDE Therapy for Eating Disorders

Recruiting at1 trial location

Overseen by Aaron Blashill, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Auburn University

No Placebo Group

Trial Summary

What is the purpose of this trial?

The goal of this clinical trial is to learn if a new intervention (Promoting Resilience to Improve Disordered Eating; PRIDE) can decrease internalized stigma and increase the ability to cope effectively with stressors in sexual minority populations diagnosed with eating disorders. The main question it aims to answer is: Will an eating disorders treatment focused on decreasing internalized stigma and increasing sexual minority stress coping self efficacy in sexual minority populations? Participants Will * Complete a telephone screen with study staff to determine preliminary eligibility for the study * Undergo a behavioral eligibility screening that includes structured clinical interviewing in order to determine proper diagnosis of an eating disorder along with ensuring absence of non-eating disorder diagnoses * Complete self-report measures to determine study eligibility * Attend up to 14 weekly therapy sessions as part of the PRIDE intervention, where participants will work with qualified clinicians to address eating pathology and disordered body image along with developing effective strategies for coping with sexual minority stressors * Complete surveys upon completion of the intervention 3 and 6 months post follow-up

Research Team

Tiffany Brown, PhD

Principal Investigator

Auburn University

Aaron Blashill, PhD

Principal Investigator

San Diego State University

Eligibility Criteria

This trial is for sexual minority individuals diagnosed with eating disorders. Participants must complete a phone screening, a clinical interview to confirm their diagnosis, and self-report measures for eligibility. They cannot have other non-eating disorder diagnoses that could interfere with the study.

Inclusion Criteria

Resides (and plans to continue to reside for the study duration) in California or one of the Psychology Interjurisdictional Compact (PSYPACT) states

Reports current (past 12 months) experience with discrimination due to sexual orientation

Speaks English

Exclusion Criteria

Inability to speak/read English

Active suicidal plans or intent

Other major untreated psychiatric diagnoses (e.g., untreated bipolar disorder, untreated psychosis)

Treatment Details

Interventions

• Promoting Resilience to Improve Disordered Eating (Behavioural Intervention)

Trial Overview The PRIDE intervention is being tested to see if it can reduce internalized stigma and improve coping with stress related to being a sexual minority. It involves up to 14 weekly therapy sessions focused on addressing eating disorders and body image issues while enhancing resilience against minority stressors.

Participant Groups

Group I: Psychotherapy Experimental Treatment 1 Intervention

Participants in this arm will experience the PRIDE intervention. PRIDE is a 14-session treatment that incorporates aspects of cognitive behavioral therapy for eating disorders (CBT-E) and SM-affirmative therapy. CBT-E aspects of treatment include in-session weighing, self-monitoring (food logs), regular eating, and techniques to address overvaluation of weight and shape. SM-affirmative therapy techniques include discussing the impact of minority stress on health, resilience, and strength within the SM community, specific manifestations of minority stress on eating and body image, current coping strategies, emotion regulation skills, and developing mindful, present-focused reactions to minority stress.

Who Is Running the Clinical Trial?

Auburn University

Lead Sponsor

Trials

81

Recruited

14,600+

Dr. Christopher B. Roberts

Auburn University

Chief Executive Officer since 2022

PhD in Chemical Engineering from the University of Notre Dame

Dr. Fred Kam

Auburn University

Chief Medical Officer since 2005

MD from the University of Alabama at Birmingham

San Diego State University

Collaborator

Trials

182

Recruited

119,000+

William Tong

San Diego State University

Chief Executive Officer since 2023

PhD in Chemistry from Iowa State University

Ramin Farzaneh-Far

San Diego State University

Chief Medical Officer since 2024

MD